TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: Overweight and Obesity in Preschool Children, Prevalence and Prevention - Family Based Health Interventions for Child Health
Brief Summary: To evaluate the effects of a family-based intervention program intended for parents of pre-school children (4-6 y) with overweight and obesity (according to Cole et al), and to investigate if treatment has an effect on metabolic parameters. In a randomised controlled trial evaluate the three separate family based intervention programs and to investigate if treatment has an effect by correlating the parameters described above with BMI, before and after the intervention program.


Options:
A: Intake of vegetables and fruit (One month)
B: Primary Outcome Measure: BMI (6 months, 1 year, 2 year, 5 year)
C: Infant weight for height (One year after study entry)
D: N/A

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Overweight and Obesity in Preschool Children, Prevalence and Prevention - Family Based Health Interventions for Child Health
Brief Summary: To evaluate the effects of a family-based intervention program intended for parents of pre-school children (4-6 y) with overweight and obesity (according to Cole et al), and to investigate if treatment has an effect on metabolic parameters. In a randomised controlled trial evaluate the three separate family based intervention programs and to investigate if treatment has an effect by correlating the parameters described above with BMI, before and after the intervention program.


Options:
A: Primary Outcome Measure: BMI (6 months, 1 year, 2 year, 5 year)
B: Primary - Body Mass index (2 years)
C: Body mass index (BMI) at 1 year.
D: Percent BMI overweight for child and parent (baseline-6,12,18, 24 months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Overweight and Obesity in Preschool Children, Prevalence and Prevention - Family Based Health Interventions for Child Health
Brief Summary: To evaluate the effects of a family-based intervention program intended for parents of pre-school children (4-6 y) with overweight and obesity (according to Cole et al), and to investigate if treatment has an effect on metabolic parameters. In a randomised controlled trial evaluate the three separate family based intervention programs and to investigate if treatment has an effect by correlating the parameters described above with BMI, before and after the intervention program.


Options:
A: % Body Fat (Boys) (Baseline and 3 years); BMI Z-score (Boys) (Baseline and three years); % Body Fat (Girls) (Baseline and 3 years); BMI Z-score (Girls) (Baseline and three years)
B: Growth trajectories (using BMI, waist circumference), body composition (3 months)
C: Primary Outcome Measure: BMI (6 months, 1 year, 2 year, 5 year)
D: Change in Child Body Mass Index (BMI Z-score) (Change from Baseline at 12 and 21 months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Overweight and Obesity in Preschool Children, Prevalence and Prevention - Family Based Health Interventions for Child Health
Brief Summary: To evaluate the effects of a family-based intervention program intended for parents of pre-school children (4-6 y) with overweight and obesity (according to Cole et al), and to investigate if treatment has an effect on metabolic parameters. In a randomised controlled trial evaluate the three separate family based intervention programs and to investigate if treatment has an effect by correlating the parameters described above with BMI, before and after the intervention program.


Options:
A: Primary Outcome Measure: BMI (6 months, 1 year, 2 year, 5 year)
B: fasting blood glucose (Baseline to 10 months postpartum); weight (body mass index) (Baseline to 10 months postpartum)
C: Body Mass Index score(BMI sds) at the age 6 years to monitor the effectiveness of the intervention (5 years)
D: Child anthropometry (Baseline. Up to 12 months. Up to 24 months.); Child food intake (Baseline. Up to 12 months. Up to 24 months.); Child health (Baseline. Up to 12 months. Up to 24 months.); Distribution of food intake within the household (Baseline. Up to 12 months. Up to 24 months.); Household food security (Baseline. Up to 12 months. Up to 24 months.); Maternal nutrition knowledge (Baseline. Up to 12 months. Up to 24 months.)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Overweight and Obesity in Preschool Children, Prevalence and Prevention - Family Based Health Interventions for Child Health
Brief Summary: To evaluate the effects of a family-based intervention program intended for parents of pre-school children (4-6 y) with overweight and obesity (according to Cole et al), and to investigate if treatment has an effect on metabolic parameters. In a randomised controlled trial evaluate the three separate family based intervention programs and to investigate if treatment has an effect by correlating the parameters described above with BMI, before and after the intervention program.


Options:
A: Primary Outcome Measure: BMI (6 months, 1 year, 2 year, 5 year)
B: Absolute change in mean accelerometry counts over 6 days (baseline, end of intervention, six months after end of intervention)
C: Change in EPAO-SR Scores from Baseline to Post-intervention (Measures collected at baseline (2-4 weeks prior to the intervention) and post-intervention (1-3 weeks following the intervention))
D: Change in child's fruit and vegetable intake as measured by short dietary screener (Baseline to 4 months, 12 month follow-up, 16-month follow-up, 24-month follow-up, and 28-month follow-up); Change in child's fruit and vegetable intake as measured by 24-hour dietary recall (Baseline to 4 months, 16-month follow-up, and 28-month follow-up); Change in child's intake of sugar-sweetened beverages and processed snacks as measured by short dietary questionnaire (Baseline to 4 months, 12-month follow-up, 16-month follow-up, 24-month follow-up, and 28-month follow-up); Change in child's intake of sugar-sweetened beverages and processed snacks as measured by 24-hour dietary recall (Baseline to 4 months, 16-month follow-up, and 28-month follow-up); Change in child's caloric intake as a percent of estimated energy requirements (Baseline to 4 months, 16-month follow-up, and 28-month follow-up); Change in child's dermal carotenoid levels (Baseline to 4 months, 16-month follow-up, and 28-month follow-up); Change in child's diet quality (Baseline to 4 months, 16-month follow-up, and 28-month follow-up)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Overweight and Obesity in Preschool Children, Prevalence and Prevention - Family Based Health Interventions for Child Health
Brief Summary: To evaluate the effects of a family-based intervention program intended for parents of pre-school children (4-6 y) with overweight and obesity (according to Cole et al), and to investigate if treatment has an effect on metabolic parameters. In a randomised controlled trial evaluate the three separate family based intervention programs and to investigate if treatment has an effect by correlating the parameters described above with BMI, before and after the intervention program.


Options:
A: Child BMI Z-score (Pre-intervention); Child BMI Z-score (post-intervention); Child BMI Z-score (6-months post-intervention); Child BMI Z-score (12-months post-intervention)
B: Child BMI
C: To evaluate and compare in overweight children the effectiveness of the following interventions: a parent-centered dietary modification program; a physical activity skill development program; and a parent-centered dietary modification + physical activity skill development program.
D: Primary Outcome Measure: BMI (6 months, 1 year, 2 year, 5 year)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Dehydroepiandrosterone (DHEA) Treatment in Women and Men Experiencing Hypoactive Sexual Desire Disorder: Modulation of Sexual Libido by Androgens and Neurosteroids
Brief Summary: Hypoactive Sexual Desire Disorder (HSDD) is a common syndrome characterized by low sexual desire causing marked distress. The involvement of DHEA in sexual function is unknown, however, DHEA treatment increased desire in depressed subjects. In the current research, we will treat 45 women and men suffering from low sexual desire with DHEA or placebo for 6 weeks. The study's primary goal is to determine the effect of DHEA treatment on sexual desire, and to find if there is a connection between levels of hormones and change in desire. Outcome measures will include hormonal levels and psychological state. Our secondary goal is to compare baseline hormones measures in individuals with low sexual desire to normal controls. For that purpose we will measure the hormonal baseline levels among 20 normal subjects.


Options:
A: Fatigue (prospective)
B: Total satisfying sexual activity over 24 weeks (6, 12, 24, 36, and 52 weeks)
C: N/A
D: blood and urine tests (beginning of treatment, and after six weeks of treatment.)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM.
Brief Summary: The study is a prospective, randomly controlled pivotal trial, designed to test the efficacy and safety of a medical device, the NovoTTF-100A, as an adjuvant to the best standard of care in the treatment of newly diagnosed GBM patients. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.


Options:
A: Progression Free Survival (PFS) time (5 years)
B: Progression-free Survival (from the date of randomisation to the date of first progression or death due to any cause, until 6 months from the date the last patient finished trial treatment (the day after the date that the last trial drug was taken))
C: Survival 6 mo (Proportion of alive participants at 6 months)
D: Overall Survival (Time to event)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM.
Brief Summary: The study is a prospective, randomly controlled pivotal trial, designed to test the efficacy and safety of a medical device, the NovoTTF-100A, as an adjuvant to the best standard of care in the treatment of newly diagnosed GBM patients. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.


Options:
A: Progression Free Survival (PFS) time (5 years)
B: N/A
C: Evaluation of the treatment impact on progression-free survival (5 years)
D: Overall survival (12 months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM.
Brief Summary: The study is a prospective, randomly controlled pivotal trial, designed to test the efficacy and safety of a medical device, the NovoTTF-100A, as an adjuvant to the best standard of care in the treatment of newly diagnosed GBM patients. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.


Options:
A: Percentage of Participants Achieving Progression-Free Survival (PFS) Without Disease Progression or Death at 6 Months (6 months)
B: median overall survival (1 year)
C: Overall survival (12 months)
D: Progression Free Survival (PFS) time (5 years)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM.
Brief Summary: The study is a prospective, randomly controlled pivotal trial, designed to test the efficacy and safety of a medical device, the NovoTTF-100A, as an adjuvant to the best standard of care in the treatment of newly diagnosed GBM patients. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.


Options:
A: median overall survival (1 year)
B: Incidence of neuropsychological and neuroendocrine function in the two arms
C: Number of Participants With Treatment Related Adverse Events (2 months)
D: Progression Free Survival (PFS) time (5 years)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM.
Brief Summary: The study is a prospective, randomly controlled pivotal trial, designed to test the efficacy and safety of a medical device, the NovoTTF-100A, as an adjuvant to the best standard of care in the treatment of newly diagnosed GBM patients. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.


Options:
A: Progression Free Survival (PFS) time (5 years)
B: Progression-free Survival (PFS) as Assessed by the Investigator (Time interval between the date of randomization and the earlier of the date of disease progression or the date of death due to any cause (up to 9.9 months)); Progression-free Survival (PFS) as Assessed by an Independent Radiologist: Randomized Phase (Time interval between the date of randomization and the earlier of the date of disease progression or the date of death due to any cause (up to 9.9 months))
C: Overall Survival (During treatment and every three months from end of treatment through end of study or approximately up to 5 years.)
D: Progression-Free Survival (PFS) (Randomization until progressive disease (PD) or initiation of antitumor therapy in the absence of PD or death, assessed every 6 weeks (up to 112 weeks))

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: The Evaluation of Cow Milk-Based Formulas - Functional Proteins
Brief Summary: The purpose of this study is to look at the function of infant formula components to optimize the nutritional content and functionality of a marketed routine infant formula.


Options:
A: Weight Gain Velocity (0 - 16 weeks)
B: Body mass index BMI: derived from measured body height (m) and body weight (kg) as body weight / height² (At age 11 years and 18 years)
C: mean weight gain (3 months)
D: N/A

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Pharmacogenetic Studies on Attention Deficit Hyperactivity Disorder
Brief Summary: The ultimate goal of this study is to find the association between specific polymorphism of candidate genes and medication response in attention deficit hyperactivity disorder (ADHD) patients. These results will lead the investigators' team: (1) to resolve controversies over inconsistent findings in previous pharmacogenetic studies; (2) to study the medication effect on the neuropsychological functions that are useful candidate endophenotypes for ADHD; (3) to delineate the nature and the effect of gene-gene interaction in the drug response of ADHD patients.


Options:
A: Dermal Reactions (7 weeks)
B: N/A
C: Incidence of adverse events; Changes in physical examinations, clinical laboratory tests, vital signs, sleep quality, appetite, and tics
D: NCBRF-TIQ D-Total Score (Measured at baseline and Weeks 3, 4, 5, 6, 7, 8, 9)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy
Brief Summary: The purpose of this study is to gather information about the use of an investigational drug called Ramucirumab in adenocarcinomas of the stomach or gastroesophageal junction.


Options:
A: Overall Survival (3 years)
B: Progression free survival (8 weeks)
C: Overall Survival (OS) (Randomization up to 28 months post-randomization)
D: Progression-Free Survival (PFS) Determined by an Independent Review Facility (Tumor assessments every 9 weeks from randomization to IRF-determined PD or death from any cause, whichever occurred first, up to the primary completion date (up to 3 years, 3 months))

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy
Brief Summary: The purpose of this study is to gather information about the use of an investigational drug called Ramucirumab in adenocarcinomas of the stomach or gastroesophageal junction.


Options:
A: Overall Survival (OS) (Randomization up to 28 months post-randomization)
B: Progression-free Survival (Treatment will continue until disease progression or intolerable toxicity, up to 2 years)
C: Progression-Free Survival (PFS) (Randomization to measured PD or date of death from any cause (up to Month 25.0))
D: Overall Survival (OS)- Phase 3 (Date of randomization until death (up to 2 years 3 months)); Overall Survival (OS) - Phase 2 (Dose Selection Portion of the Study) (Date of randomization until death (up to 1 year))

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy
Brief Summary: The purpose of this study is to gather information about the use of an investigational drug called Ramucirumab in adenocarcinomas of the stomach or gastroesophageal junction.


Options:
A: Overall Survival (OS) (Randomization up to 28 months post-randomization)
B: response (WHO criteria) (staging every 8 weeks)
C: Overall Survival (Survival contact from the date of randomization and then every 8 weeks following objective disease progression and in the 7 days following OS Data Cut off (DCO); Time point(s) at which outcome measure is assessed up to 4 years)
D: Progression free survival (8 weeks)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: The Outcome of Treatment of Traumatised Refugees With Trauma-Focused Cognitive Behavioural Therapy and / or Antidepressants - a Randomised Controlled Trial
Brief Summary: The purpose of the study is to investigate the effect of treatment of traumatized refugees with a diagnosis of Post-Traumatic Stress Disorder (PTSD). The existing evidence point towards antidepressants of the type SSRI and trauma-focused cognitive Behavioural Therapy being the most effective treatments of PTSD, but very little evidence of treatment effects exist for the group of multitraumatized refugees. This study therefore seeks to investigate the treatment effect of 6 months drug therapy with antidepressants (Sertraline and/ or Mianserine) and/or trauma-focused cognitive behavioral therapy. A total of 200 individual will undergo treatment. They will be randomized to 4 different groups: antidepressants, psychotherapy, a combination og drug and psychotherapy and a waiting list. Outcome measures include symptoms, life quality and function. Patients with a diagnosis of drug abuse or psychosis will not be included. The hypothesis is that a combination of antidepressants and psychotherapy will be more effective than either of the two treatment regimes on their own.


Options:
A: PTSD Symptoms (Post-treatment, ten weeks); Depression Symptoms (Measured at Post-Treatment, at 10 weeks); State Anxiety (Measured at Post-Treatment, at 10 weeks)
B: PTSD Symptoms (8 weeks)
C: Score on Harvard Traume Questionnaire (PTSD) (before entry, after 6 months treatment and at follow up)
D: Changes in CAPS Scores. (Baseline, 8 weeks)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Prospective Collection of Biological Data of Prognostic Relevance in Patients
Brief Summary: The purpose of the present study is to develop a biological prognostic index in patients with Binet stage A Chronic Lymphocytic Leukemia (CLL) who do not necessitate therapy according to NCI guidelines and to prospectively validate the proposed score system based on the absence/presence of 1, 2 or 3 unfavorable prognostic markers such as cluster of differentiation 38 (CD38) expression, Zap-70 expression and immunoglobulin heavy chain variable region (IgVH) configuration.


Options:
A: perioperative copeptin concentrations (perioperative from induction of anesthesia to the third postoperative day); composite events composed of all-cause mortality and/or major adverse cardiac and cerebrovascular events (MACCE) (12 months); myocardial injury in non-cardiac surgery (MINS) (3 postoperative days)
B: Ischemia (Holter-electrocardiogram [ECG], troponin T, ECG) (7 days postoperatively)
C: Prospective validation of the prognostic potential of a score system based on the presence/absence of three risk factors (VH mutational status, Zap-70 and CD38 expression) on Progression Free Survival (PFS ). (6 months)
D: All-cause mortality at 30-days after surgery (30 days after surgery); Myocardial injuries that were not identified clinically during the first 5 days after surgery (5 days after surgery); Composite of vascular death, nonfatal myocardial infarction, nonfatal cardiac arrest, nonfatal stroke, and mechanical assist device (30 days after surgery); Composite of vascular death, nonfatal myocardial infarction, nonfatal cardiac arrest, nonfatal stroke, and mechanical assist device (1 year after surgery)

Answer: C